Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Up 439.5% in January

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 1,760,000 shares, a growth of 439.5% from the January 15th total of 326,200 shares. Based on an average daily trading volume, of 6,950,000 shares, the short-interest ratio is presently 0.3 days. Currently, 4.8% of the shares of the company are sold short.

Cardio Diagnostics Price Performance

CDIO stock opened at $0.53 on Thursday. Cardio Diagnostics has a 52-week low of $0.19 and a 52-week high of $1.91. The company’s 50-day simple moving average is $0.74 and its 200-day simple moving average is $0.46.

Institutional Trading of Cardio Diagnostics

An institutional investor recently raised its position in Cardio Diagnostics stock. Geode Capital Management LLC increased its stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) by 97.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 364,387 shares of the company’s stock after acquiring an additional 179,978 shares during the quarter. Geode Capital Management LLC owned approximately 0.90% of Cardio Diagnostics worth $334,000 at the end of the most recent reporting period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.